Savvy Trades and Investments

[Trent Blair]

CZO.V CRPOF Our valuation model takes a very conservative stance and does not account for the commercialization of Ceapro’s avenanthramides and/or beta glucan as pharmaceutical products. In the near future, we expect to see results from the studies and trials that are being conducted that support efficacy for treating high cholesterol and inflammation. If these potential candidates are eventually approved, we anticipate material upside to our Ceapro valuation. I definitely expect them to be able to commercialize most if not all of these products. They're raising about $5 million in the private placement so I think they should have the clinical trials and manufacturing expansion easily funded. http://finance.yahoo.com/news/ceapro-inc-announces-brokered-private-110500949.html http://finance.yahoo.com/news/czo-v-ceapro-reports-accelerating-132500549.html